Physician profile
Yulam Chiu
NPI 1104886704
$3,209.99
in general payments reported to CMS, 2019-2025
21 companies · $498 in 2025
The $498 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $138 · 2021: $398 · 2022: $811 · 2023: $548 · 2024: $416 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,124.25 | 2021-2025 | Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $316.50 | 2019-2025 | |
| Boston Scientific Corporation | $248.72 | 2020-2024 | Eluvia |
| Janssen Pharmaceuticals, INC | $224.01 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $193.20 | 2022-2025 | Camzyos, Eliquis |
| Cook Medical LLC | $191.97 | 2019-2020 | |
| Edwards Lifesciences Corporation | $165.12 | 2023 | Inspiris Resilia Aortic Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.62 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.01 | 2019-2025 | Jardiance |
| Philips North America LLC | $106.60 | 2022 | |
| Pfizer INC. | $75.85 | 2019-2025 | |
| Biosense Webster, INC. | $62.53 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $52.98 | 2021-2025 | Uptravi, Opsumit |
| Amarin Pharma, INC. | $52.09 | 2019-2022 | |
| Daiichi Sankyo INC. | $43.32 | 2024-2025 | Injectafer |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.57 | 2021-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $29.74 | 2019 | |
| Alnylam Pharmaceuticals INC. | $20.29 | 2022 | |
| Cardiva Medical, INC. | $17.66 | 2021 | |
| Esperion Therapeutics, INC. | $14.05 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yulam Chiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.